logo

For the Inventor, By the Inventor

Salt Lake City, UT, United States of America

Arrien Pharmaceuticals LLC


USPTO Granted Patents = 14



Forward Citations = 32

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal Hariprasad Vankayalapati (14 out of 50 patents)

silverMedal Venkatakrishnareddy Yerramreddy (9 out of 9 patents)

bronzeMedal Rajendra P Appalaneni (9 out of 9 patents)

4.  Y Venkata Krishna Reddy (3 out of 3 patents)

5.  Venu Babu Ganipisetty (3 out of 3 patents)

6.  Sureshkumar Talluri (3 out of 3 patents)

7.  Paramareddy Gangireddy (2 out of 2 patents)

8.  Y Vekata Krishna Reddy (1 out of 1 patent)


14 patents:

1. 11053221 - Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity (2021-07-06),
2. 10682358 - Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2020-06-16),
3. 10172866 - Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2019-01-08),
4. 9962382 - Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors (2018-05-08),
5. 9951062 - Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2018-04-24),
6. 9890153 - Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2018-02-13),
7. 9834551 - Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors (2017-12-05),
8. 9669028 - [object Object] (2017-06-06),
9. 9446047 - Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2016-09-20),
10. 9359315 - [object Object] (2016-06-07),
11. 9260426 - Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2016-02-16),
12. 9206188 - [object Object] (2015-12-08),
13. 9187473 - [object Object] (2015-11-17),
14. 8791112 - [object Object] (2014-07-29),
Arrien Pharmaceuticals is a leading biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. We specialize in novel therapies for a wide range of diseases, including cancer, autoimmune disorders, and rare genetic conditions. With a strong commitment to scientific research and collaboration, we are dedicated to improving patient outcomes and transforming the future of healthcare.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 13 2026

14 Patents

#101 in Salt Lake City, UT

#254 in Utah

#21,674 in US

#41,010 in the World

...
Salt Lake City, UT, United States of America

Arrien Pharmaceuticals LLC

Forward Citations = 32

8 inventors:

goldMedal Hariprasad Vankayalapati (14 out of 50 patents)

silverMedal Venkatakrishnareddy Yerramreddy (9 out of 9 patents)

bronzeMedal Rajendra P Appalaneni (9 out of 9 patents)

4.  Y Venkata Krishna Reddy (3 out of 3 patents)

5.  Venu Babu Ganipisetty (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com
Loading…